サイタイムに関するコメント

$マイクロン テクノロジー(MU.US)$ - Semiconductor stock in an uptrend after some momentum in the sector. Calls above $87
$ロブロックス(RBLX.US)$ - Seeing lot of dec and Jan call options coming in on this one. Looking bullish on charts Calls above $130.
$ユナイテッドヘルス・グループ(UNH.US)$ - added some calls on this one. Breaking $450 resistance level today. Looking for $460 by end of the month.
$アップル(AAPL.US)$ - another stock seeing some call activity coming in. calls above $161
$サイタイム(SITM.US)$ - S&P Dow Jones Indices Announces SiTime Will Join S&P MidCap 400, Emergent To Joint S&P SmallCap 600.  Calls above $310

$ズーム・ビデオ・コミュニケーションズ(ZM.US)$ - work from home stocks could get some momentum this week. Calls above $225
$ドキュサイン(DOCU.US)$ - another work from home stock to watch. Calls above $255
$テラドック・ヘルス(TDOC.US)$ - beaten down stock.  Stock should get some momentum after concerns over the new variant. Calls above 112
$アドバンスト・マイクロ・デバイス(AMD)(AMD.US)$ - stock bullish as long as above $152.50. Holding calls.
$サイタイム(SITM.US)$ - S&P Dow Jones Indices Announces SiTime Will Join S&P MidCap 400, Emergent To Joint S&P SmallCap 600.  Calls above $301

$テスラ(TSLA.US)$ - 'Tesla files for Gigafactory Texas approval, reveals budget for first phase' -Electrek Report.
$バイオエヌテック(BNTX.US)$ - Pfizer-BioNTech's COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents.  Calls above $325
$モデルナ(MRNA.US)$ -  stock having nice reversal on charts. Stock has gap from $300 to $330.
$ユナイテッド・パーセル・サービス(UPS.US)$ - Charts looking very good on this one. Stock is green in the red market. Calls above $213
$サイタイム(SITM.US)$ - S&P Dow Jones Indices Announces SiTime Will Join S&P MidCap 400, Emergent To Joint S&P SmallCap 600.  Calls above $275.

$SITM - STOCK PLAY
NEED IT TO BREAK OVER: $182
key indicator for MORE uptrend $185
confirmation uptrend - $185.64
mini breakout - $189.45
full breakout - $195.84
SEMI PARABOLIC - $197.63
stop loss — $168.49
& support - $141.12. $サイタイム(SITM.US)$

$インヒビカセ・セラピューティクス(IKT.US)$
$インヒビカセ・セラピューティクス(IKT.US)$
$インヒビカセ・セラピューティクス(IKT.US)$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$コーバー(CWBR.US)$
$コーバー(CWBR.US)$
..........................................
$フルクラム・セラピューティクス(FULC.US)$